# Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome

> **NCT04625738** · PHASE2 · COMPLETED · sponsor: **Central Hospital, Nancy, France** · enrollment: 30 (actual)

## Conditions studied

- COVID19 ARDS

## Interventions

- **BIOLOGICAL:** Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04625738
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-06
- **Primary completion:** 2021-05-14
- **Final completion:** 2021-09-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04625738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04625738, "Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04625738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*